← Back to guidelines
Dermatology14 papers

Mucosal lentiginous melanoma

Last edited: 4/14/2026

Overview

Mucosal lentiginous melanoma is a rare variant of melanoma that arises from mucosal surfaces, including the sinonasal, anogenital, and conjunctival regions, often with distinct genetic profiles and poorer prognoses compared to cutaneous melanomas 12.

Diagnosis

  • Biopsy confirmation is essential for diagnosis 3.
  • Genetic testing for mutations such as BRAF, NRAS, and KIT can provide prognostic information 12.
  • Presence of brisk tumor-infiltrating lymphocytes may correlate with better outcomes 1.
  • Pathologic assessment should consider unique factors like margin evaluation specific to mucosal sites 5.
  • Management

  • First-line treatment: Immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) are increasingly used, with reported 5-year overall survival rates around 42.6% 1.
  • Adjuvant therapy: Consideration of immunotherapy in adjuvant settings based on genetic profiles and clinical stage 1.
  • Surgical intervention: Primary or adjuvant surgery may be indicated depending on extent and location 3.
  • Radiotherapy: Used in cases where surgery is not feasible or as an alternative to immunotherapy 3.
  • Special Populations

  • Elderly patients: Limited specific guidance; management often tailored to comorbidities and performance status 3.
  • Comorbidities: Impact on treatment selection and tolerance, particularly for immunotherapy 1.
  • Key Recommendations

  • Utilize genetic testing for BRAF, NRAS, and KIT mutations to guide treatment decisions (Evidence: Moderate 12).
  • Consider immune checkpoint inhibitors as a first-line or adjuvant treatment option, especially in patients with brisk tumor-infiltrating lymphocytes (Evidence: Moderate 1).
  • Implement standardized pathologic reporting guidelines for mucosal melanomas to ensure consistent diagnosis and prognosis assessment (Evidence: Expert opinion 5).
  • Tailor management strategies considering patient-specific factors such as age and comorbidities (Evidence: Expert opinion 3).
  • References

    1 Tang A, Taori S, Dang S, Gardner PA, Zenonos GA, Davar D et al.. Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery 2024. link 2 Beaudoux O, Oudart JB, Riffaud L, Visseaux L, Marchal A, Lebre AS et al.. Mutational Characteristics of Primary Mucosal Melanoma: A Systematic Review. Molecular diagnosis & therapy 2022. link 3 Li L, London NR, Chen X. Malignant Mucosal Melanoma of the Eustachian Tube With Extension Into the Ipsilateral External Ear Canal: A Case Report and Review of the Literature. Ear, nose, & throat journal 2021. link 4 Smith HG, Bagwan I, Board RE, Capper S, Coupland SE, Glen J et al.. Ano-uro-genital mucosal melanoma UK national guidelines. European journal of cancer (Oxford, England : 1990) 2020. link 5 Williams MD, Franchi A, Helliwell T, Müller S, Thompson LDR. Data Set for the Reporting of Mucosal Melanomas of the Head and Neck: Explanations and Recommendations of the Guidelines From the International Collaboration on Cancer Reporting. Archives of pathology & laboratory medicine 2019. link 6 Rosenblum GA. Cryotherapy of lentiginous mosaicism. Cutis 1985. link

    Original source

    1. [1]
      Immunotherapy in the Management of Sinonasal Mucosal Melanoma: A Systematic Review.Tang A, Taori S, Dang S, Gardner PA, Zenonos GA, Davar D et al. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery (2024)
    2. [2]
      Mutational Characteristics of Primary Mucosal Melanoma: A Systematic Review.Beaudoux O, Oudart JB, Riffaud L, Visseaux L, Marchal A, Lebre AS et al. Molecular diagnosis & therapy (2022)
    3. [3]
    4. [4]
      Ano-uro-genital mucosal melanoma UK national guidelines.Smith HG, Bagwan I, Board RE, Capper S, Coupland SE, Glen J et al. European journal of cancer (Oxford, England : 1990) (2020)
    5. [5]
    6. [6]
      Cryotherapy of lentiginous mosaicism.Rosenblum GA Cutis (1985)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG